<DOC>
	<DOCNO>NCT00050817</DOCNO>
	<brief_summary>RATIONALE : - Atherothrombosis progressive generalize vascular disease result event lead myocardial infarction ( heart attack ) , stroke , vascular death . - In patient risk disease , characterize unpredictable , sudden disruption atherosclerotic plaque , may lead total occlusion artery due formation clot . The use aspirin ( blood thinner agent ) reduce major ischemic event either indicate , recommend international guideline . However , aspirin fails prevent high percentage life-threatening event . Therefore , effective blood thin therapy may provide additional clinical benefit patient . - The result CURE trial patient unstable angina demonstrate additional benefit long-term treatment ( one year ) clopidogrel , ( blood thinner agent ) , administer combination standard therapy include aspirin . The purpose CHARISMA investigate whether similar clinical benefit clopidogrel may apply broad population high-risk patient receive low-dose aspirin therapy . Such population include patient previous cardiovascular , neurovascular peripheral arterial manifestation atherothrombosis patient combination recognize risk factor atherosclerosis . OBJECTIVES : - To assess efficacy clopidogrel 75 mg once-daily comparison placebo , prevent cardiovascular morbidity/mortality . The study compare efficacy two regimen prevent occurrence major cardiovascular complication ( stroke , heart attack , cardiovascular death ) high-risk patient otherwise receive low-dose aspirin therapy ( 75-162 mg daily ) . - To evaluate safety clopidogrel population , specifically incidence fatal severe bleeding ( per GUSTO definition ) , order estimate global benefit clopidogrel patient population .</brief_summary>
	<brief_title>Clopidogrel High Atherothrombotic Risk Ischemic Stabilization , Management Avoidance ( CHARISMA )</brief_title>
	<detailed_description>TREATMENTS : - Clopidogrel ( Plavix® and/or Iscover® ) agent inhibit platelet aggregation involve clot formation . Each tablet contain 75mg clopidogrel . A matching placebo clopidogrel inactive substance look similar active clopidogrel tablet . TREATMENT PLAN : - There two treatment group ; one receive clopidogrel 75 mg ( 1 tablet qd ) , second match placebo clopidogrel ( 1 tablet qd ) . These study drug administer top low-dose aspirin ( 75-162 mg qd ) systematically prescribed patient . In addition , patient enrol CHARISMA manage appropriate risk factor atherosclerosis : eg . high blood pressure , high cholesterol , diabetes…etc . PRIMARY ENDPOINT : - Combined endpoint cardiovascular mortality , stroke , acute myocardial infarction . STUDY EXECUTION : - Some 7,600 patient per group recruit within two year . Patients observe maximum 3.5 year . STUDY TERRITORY : - Approximately 900 site throughout North/South America , Europe , Asia , Australia , South Africa .</detailed_description>
	<mesh_term>Arteriosclerosis</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<criteria>INCLUSION : Be least 45 year old comply least one four category inclusion criterion : Combination atherothrombotic risk factor ( 2 major 3 minor 1 major + 2 minor risk factor among list ) Major atherothrombotic risk factor Type I II diabetes ( drug therapy ) Diabetic nephropathy Ankle brachial index ( ABI ) &lt; 0.9 Asymptomatic carotid stenosis &gt; = 70 % At least one carotid plaque evidence intimamedia thickness ( IMT ) Minor atherothrombotic risk factor Systolic blood pressure ( SBP ) &gt; = 150 mmHg , despite appropriate therapy least 3 month Primary hypercholesterolemia Current smoke &gt; 15 cigarette per day Male &gt; = 65 year Female &gt; = 70 year and/or Documented cerebrovascular disease ( TIA IS within 5 year ) and/or Documented coronary artery disease ( stable angina document multivessel coronary disease , previous document MI , multivessel PCI CABG within 1 year , multivessel CABG old 1 year associate current angina ) and/or Documented symptomatic PAD EXCLUSION : Absolute indication use clopidogrel , highdose aspirin ( &gt; 162 mg ) , NSAIDs , oral antithrombotic drug Absolute contraindication use clopidogrel aspirin Clinical condition likely interfere followup leading inability complete trial</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Embolism</keyword>
</DOC>